Physicians' Academy for Cardiovascular Education

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

Targeting residual inflammatory risk as a strategy to lower CV risk

Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)

Inflammation as potential target for therapy to target residual risk post ACS

Aug. 27, 2016 - ESC 2016, Rome - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation

Aug. 28, 2016 - ESC 2016, Rome - Jorge Plutzky, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA - Recorded at PACE-CME symposium at ESC 2016

How to treat residual inflammatory risk?

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul Ridker, MD - Boston, MA, USA

Evolving hypotheses on the mechanisms underlying ACS

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA
##SCROLLER_ITEMS_FULL_TITLE##

Attenuating inflammation by inhibition of p38 MAP-kinase does not reduce CV endpoints in LATITUDE TIMI-60

Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Michelle O'Donoghue

Changing views on mechanisms of atherosclerosis

Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation and CV risk: Beyond statins in the treatment of atherosclerosis

Mar. 8, 2016 - Boston, MA, USA - Paul M Ridker

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation as target for therapy in atherothrombosis

Aug. 31, 2015 - ESC London - Prof Paul M Ridker
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation and Thrombosis

Sep. 29, 2015
##SCROLLER_ITEMS_FULL_TITLE##

The changing character of atherosclerotic disease

May 24, 2015 - ISA2015, Amsterdam - Prof. Peter Libby

Cardiovascular Inflammation and Immunity in Atherosclerosis:

June 7, 2015 - Amsterdam
##SCROLLER_ITEMS_FULL_TITLE##

Is inflammation reduction key for targeting residual risk, beyond lowering LDL-c?

Oct. 18, 2014 - Snapshot 2014 - Prof. Paul M Ridker, MD

Statin-loaded HDL nanoparticles

Jan. 23, 2014 - Raphaël Duivenvoorden - Raphaël Duivenvoorden
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation: targets for intervention

Oct. 3, 2013 - Snapshot 2013 - Ulf Landmesser

Inflammation & cardiovascular disease: Exploring new options for intervention

Sep. 30, 2013

Anti-inflammatory changes in response to PCSK9 antibody treatment in monocytes of FH patients

Feb. 20, 2017 - Bernelot Moens SJ et al., - Eur Heart J 2017

Circulating monocytes of FH patients not on statins showed a pro-inflammatory phenotype and intracellular lipid accumulation, which was reversed upon treatment with PCSK9 antibodies.

GLP-1 agonist lowers CV biomarkers in high-risk T2DM patients

Jan. 25, 2017 - von Scholten BJ, et al. - Diabetes Obes Metab. 2017

In T2DM patients with albuminuria, liraglutide treatment associates with reductions in circulating levels of CV risk biomarkers.

Amygdalar activity in response to stress predicts development of subsequent CV events

Jan. 19, 2017 - Tawakol A, et al., - The Lancet. 2017.

First study in humans to show a link between activity in the amygdala to subsequent CV events, likely via upregulation of haemopoietic tissue activity and increased atherosclerotic inflammation.

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada
Epigenetic apabetalone or RVX-208 that alters chromatin structure and gene activity gave clinical benefit in phase 2 study.

AHA 2016 The orally active epigenetic drug RVX-208 or apabetalone that alters gene activity by modifying chromatin structure, lowered the incidence of MACE in a phase 2b study. This effect could not entirely be attributed to an effect on HDL, explains dr. Norman Wong.

Smoking heaviness associated with CVD risk-associated inflammatory markers

Dec. 14, 2016 - King CC, Arterioscler Thromb Vasc Biol, 2017

Smoking heaviness independently related to urinary F2:Cr ratio, myeloperoxidase and WBC counts. F2:Cr ratio and WBC were also reduced after cessation. 

hsCRP levels combined with the extent of carotid atherosclerosis provide additional prognostic information

Dec. 5, 2016 - Mayer FJ et al., Stroke. 2016

The combination of the extent of carotid atherosclerosis and inflammatory status provided additional prognostic information for patients with asymptomatic carotid atherosclerosis.

Targeting residual inflammatory risk as a strategy to lower CV risk

Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)
Residual CV risk consists of cholesterol and inflammatory residual risk. How can these aspects be addressed to lower CV risk?

CSI ROME Nicole Jaspers and Manon Slob interview Prof. Paul Ridker about the concept of residual risk and how the different forms may be targeted with novel therapeutic strategies to further lower CV risk.

IL-1β inhibitor has no positive effect on arterial structure or function

Oct. 12, 2016 - Choudhury RP, et al, JACC, 2016

Although the IL-1β inhibitor canakinumab reduced inflammation markers, there was no effect on measures of vascular structure or function in patients with T2DM and established CV disease. 

Elevated levels of four inflammatory biomarkers associated with increased risk of stroke

Sep. 12, 2016 - Shoamanesh A et al., Neurology 2016

The predictive ability of the Framingham Stroke Risk Profile score for incident ischaemic stroke was significantly improved with addition of 4 inflammatory biomarkers:  CRP, tHcy, TNFR2, and VEGF.

Inflammation as potential target for therapy to target residual risk post ACS

Aug. 30, 2016 - news
Inflammation as potential target for therapy to target residual risk post ACS

After treatment with high-intensity statins, patients can still have residual cholesterol risk or residual inflammatory risk. This means that patients still have either high levels of LDL-c, but normal high sensitivity C-reactive protein (hsCRP) or normal LDL-c but high hsCRP

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

Aug. 28, 2016 - news

At the 'A novel approach for high cv risk patients with diabetes: the potential of epigenetics' symposium, held at the ESC Congress 2016 in Rome, Kausik Ray spoke about therapeutic targets to further lower CV risk.

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation

Jorge Plutzky, MD - Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Aug. 28, 2016 - Jorge Plutzky, MD - Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

At the 'A novel approach for high cv risk patients with diabetes: the potential of epigenetics' symposium, held at the ESC Congress 2016 in Rome, Jorge Plutzky spoke about BET inhibition as a nover pathway for CV risk reduction.